Presenting a Truly Non-Invasive Glucose Monitor for Home Use

A. Gal¹, I. Harman-Boehm², A. Drexler³, E. Naidis¹, Y. Mayzel¹, N. Goldstein¹, K. Horman¹

1) Integrity Applications Ltd., Ashkelon, Israel: 2) Internal Medicine and the Diabetes Unit. Soroka University Medical Center, Beer-Sheva, Israel: 3) Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

Backaround

One of the keys to achieve tight glycemic control in people with diabetes is through a routine, frequent monitoring of blood glucose (BG). However, invasive BG monitoring is underutilized, mostly since it involves painful, inconvenient and costly process, Non-Invasive (NI) device for home use is expected to overcome these barriers and thus increase BG monitoring adherence. *GlucoTrack*®, a CE Mark approved truly NI device for self-monitoring of BG at home and home-alike environments, is suggested as an available solution.

Gluco Track comprises a Main Unit (MU), which drives different sensors, located at a Personal Ear Clip (PEC) (Figure 1-A). The PEC is clipped externally to the earlobe, to commence a real-time spot measurement. Prior to conducting measurements with a new PEC, an individual calibration procedure (-2 hours) is required. Calibration is performed by using invasive capillary fingertip BG as a reference. PEC life span is 6 months; therefore Bi-annual replacement of the PEC is necessary.

Performing a measurement (Figure 1-B) is convenient, easy, and takes less than a minute. Glucose readings are heard and displayed on a color touch-screen of a smartphone sized MU.



tional use only. The device is CE Mark approved. Caution: Investigational device Limited by federal (Unit

Figure 1: (A) GlucoTrack Model DF-F; (B) Conducting a Measurement



Method

- **GlucoTrack** eligibility for home use was assessed according to:
- Calibration validity period: evaluated by clinical trials conducted for up to 6 months (towards regulatory process):
- Evaluation of user impact, based on comparison between the performance analysis of two groups:
- ✓ Clinic group, where measurements were performed by a skilled medical team;

of Data

Points

6.507

480

429

481

438

414

8,749

of Subjects

138

14

10

10

10

9

138

- ✓ Home Simulated group, where measurements were conducted by the subjects themselves, after a brief training.
- * Feedback analysis regarding user satisfaction; questionnaires were completed at the end of the trials by all participants.

Results

Months Post

Calibration

1st month

2nd month

3rd month


4th month

5th month

6th month

Accumulated

(CEG) and Absolute Relative Difference (ARD). The performance analysis was performed on 8.749 data points from 138 subjects (64 F, 74 M; 20 type 1, 118 type 2; Age: 18-81 years; BMI: 18.3-47.3 kg/m²). No degradation in performance was noticed as a function of time elapsed from calibration (Table 1).



96.3 Gluco Track performances were maintained across Clinic and Home Simulated aroups, as presented in Table 2.

95.7

38.6

41.7

30.2


30.4

26.7

24.6

Table 2: Device Accuracy in Clinic and Home Simulated Groups

	Clinic Group	Home Simulated Group
# of Subjects	96	42
# of Data Points	6,895	1,854
CEG A+B Zones (%)	96.3	96.2
CEG A Zone (%)	42.0	40.3
Mean ARD (%)	30.3	30.7
Median ARD (%)	24.3	25.5



- * The clinical trial results demonstrate acceptable accuracy in both Clinic and Home Simulated groups, indicating low user impact. This implies that users guickly overcome device learning curve;
- The results suggest validity of GlucoTrack calibration for the entire life span of the PEC (6 months) without a need for re-calibration:
- Users' feedback show:
- ✓ High satisfaction from GlucoTrack;
- ✔ Willingness to use the device more frequently than the invasive devices.

GlucoTrack is a user friendly device, which provides pain-free and inexpensive use, without the need to be continuously worn, and is technically available for use.

GlucoTrack advantages emphasize its suitability for home use, which consequentially lead to better BG monitoring adherence and tighter glucose control.



102 Ha'Avoda St., P.O. Box 432 Ashkelon 7810301 Israel Phone: +972 (8) 675-7878 Fax: +972 (8) 675-7850 e-mail: info@integrity-app.com www.integrity-app.com

EASD, Barcelona, Spain, September 2013